Jasper Therapeutics, Inc. (JSPR) - Form 8-K Summary
Business Context and Reporting Period
Jasper Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 14, 2026. The filing serves to report the company's financial results for the quarter ended June 30, 2026, and provides a corporate update. The company's principal executive offices are located in Redwood City, California.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a cover report referencing a press release (Exhibit 99.1) where these details are disclosed. The filing confirms the company has Voting Common Stock (JSPR) and Redeemable Warrants (JSPRW) trading on The Nasdaq Stock Market LLC.
Material Changes
The filing text does not provide specific data to compare current period performance against prior comparable periods. It only indicates that a press release containing the quarterly results and corporate update was issued on the date of the report.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed within the text of this Form 8-K. The document states that the information is furnished under Item 2.02 and Item 9.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2026) for specific Q2 2026 financial figures.
- Verify the status of the Redeemable Warrants (JSPRW) and their exercise price of $115.00.
- Confirm the company's cash runway and burn rate from the full press release, as this 8-K does not list liquidity metrics.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate update.